Dr. Morgan on Olaparib for Metastatic Castration-Resistant Prostate Cancer

Alicia Morgan, MD
Published: Wednesday, Dec 20, 2017



Alicia Morgan, MD, Mather Hospital, discusses the role of olaparib (Lynparza) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Olaparib is a PARP inhibitor for the treatment of patients with mCRPC. In the TOPARP-A study, men were selected if they had undergone multiple prior therapies and were treatment refractory, explains Morgan. The response rate of patients who had DNA repair defects was 88%, based on prostate-specific antigen (PSA) response.

According to Morgan, the response was higher than what is traditionally expected in a regular clinical trial.
 


Alicia Morgan, MD, Mather Hospital, discusses the role of olaparib (Lynparza) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Olaparib is a PARP inhibitor for the treatment of patients with mCRPC. In the TOPARP-A study, men were selected if they had undergone multiple prior therapies and were treatment refractory, explains Morgan. The response rate of patients who had DNA repair defects was 88%, based on prostate-specific antigen (PSA) response.

According to Morgan, the response was higher than what is traditionally expected in a regular clinical trial.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x